Becton Dickinson & Co (BDX) has been receiving significant attention in the bio-tech market. The company is seen as a
strong value and
growth stock due to increased
holdings by Tredje AP fonden and First Eagle Investment Management LLC. The
acquisition of
Critical Care from Edwards Lifesciences is completed which is strategic for BDX's path to becoming an advanced monitoring technology leader. This acquisition, combined with surpassing their
Scope 1 and 2 Reduction Milestones for FY 2023, and
raised fiscal 2024 guidance, strengthens BDX’s market position and share value. However, it's worth noting a slight stock slip due to outlook. BDX is also surrounded by
speculation of being
undervalued according to intrinsic calculation suggesting potential value growth in the future. Ongoing initiatives include developing
companion diagnostics for Cancer and other diseases in partnership with
Quest Diagnostics, addressing supplier issues impacting their blood culture vials and expansion of smart connected care solutions. The appointment of
Michael Feld as president of its Life Sciences segment indicates strategic shifts in BDX, reaffirming its commitment towards innovation.
Becton Dickinson and BDX News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Fri, 20 Sep 2024 01:11:13 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor 6
